Biocon, Mylan launch cancer drug in US market

Ogivri, available in a 420mg multi-dose vial and a 150mg single-dose vial, will be used for treatment of all types of breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35UW9uo
via IFTTT